stockholders$(8,220,785)$(9,768,246)Net Loss Per Share - Basic and Diluted$(0.38)$(1.30)Weighted Average Common Shares OutstandingBasic and diluted (include pre-funded warrants from the October 2025 offering)21,495,2747,492,460CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)20252024Cash Flows From Operating Activities:Net loss$(9,393,889)$(10,281,246)Adjustments to reconcile net loss to net cash used in operating acti ...

Financing Activities15,125,489-Net Change in Cash and Cash Equivalents3,370,543-Cash and Cash Equivalents – Beginning of Period3,924,908112Cash and Cash Equivalents – End of Period$7,295,451$112Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:Interest Paid$14,460$-SOURCE Citius Oncology, Inc.## 21%[more press release views with Request a Demo]## Also from this source### Citius Oncology Expands International Distribution of LYMPHIRâ"¢ to European Union Through Exclusive Agreement w ...

Core Insights - Citius Pharmaceuticals successfully launched LYMPHIR, a novel cancer immunotherapy, in December 2025, marking a significant advancement in treatment options for cutaneous T-cell lymphoma (CTCL) patients [2][5][7] Business Highlights - The launch of LYMPHIR represents the first new systemic therapy for CTCL since 2018, showcasing the company's commitment to providing impactful treatments [2] - Citius Pharma has engaged with the FDA to advance other products, including Mino-Lok, and is exploring additional indications for LYMPHIR [2][5] - The company has secured distribution agreements with three leading U.S. pharmaceutical wholesalers and access to LYMPHIR in 19 international markets [5] - LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation, facilitating coverage and reimbursement [5] Financial Highlights - Citius Pharma raised approximately $61 million in gross proceeds from capital raises, with $25 million from strategic financings for Citius Pharma and $36 million for Citius Oncology [5] - As of September 30, 2025, the company reported cash and cash equivalents of $4.3 million, with no revenues reported for the fiscal year [5][6] - Research and development expenses decreased to $9.2 million from $11.9 million in the previous year, while general and administrative expenses slightly increased to $18.5 million [5][6] - The net loss for the fiscal year was $39.7 million, or $3.38 per share, compared to a net loss of $40.2 million, or $5.97 per share, in the previous year [6][13] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [7] - The company holds robust intellectual property protections, including orphan drug designation and pending patents, which enhance its competitive positioning in the oncology market [7]

Core Insights - Citius Oncology has launched an innovative AI platform to enhance its commercial strategies and support the upcoming launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL) [1][2][5] - The AI platform utilizes machine learning to identify treatment patterns and target prescribers effectively, thereby improving patient care and clinical decision-making [2][4][5] - LYMPHIR is a targeted immune therapy approved by the FDA in August 2024 for relapsed or refractory CTCL, with a market potential exceeding $400 million [6][7][32] Group 1: AI Platform and Commercial Strategy - The proprietary AI platform is designed to refine targeting and enhance the efficiency of the salesforce by providing data-informed engagement with healthcare providers [1][3] - It continuously learns from real-world data and marketing performance analytics, delivering predictive insights for tailored customer journeys [4] - The platform aims to optimize the commercial infrastructure and accelerate healthcare provider education [5] Group 2: Product Overview and Market Potential - LYMPHIR is indicated for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy [10] - The therapy is a recombinant fusion protein that targets IL-2 receptors on tumor cells, leading to cell death and enhanced antitumor activity [6] - Citius Oncology estimates the initial market for LYMPHIR to exceed $400 million, indicating significant growth potential in an underserved market [32]

Financial Overview - Citius Pharmaceuticals raised $12.5 million in gross financings during the fiscal third quarter ended June 30, 2025, with an additional $9 million raised in July 2025 for LYMPHIR pre-launch initiatives [1][3] - The company reported a net loss of $9.2 million, or $0.80 per share, for the quarter, an improvement from a net loss of $10.6 million, or $1.57 per share, in the same quarter of the previous year [7][13] Business Development - Citius is transitioning from a development-stage enterprise to a fully integrated commercial organization, with final preparations for the U.S. launch of LYMPHIR™ planned for the fourth quarter of 2025 [2][3] - The company has completed major launch-enabling activities, including commercial-scale manufacturing and distribution agreements, indicating readiness to deliver LYMPHIR to patients with cutaneous T-cell lymphoma [3][6] Financial Results - Research and development expenses for the quarter were $1.6 million, down from $2.8 million in the same quarter of 2024 [7][15] - General and administrative expenses were $4.4 million, compared to $4.8 million in the prior year [7][15] - Cash and cash equivalents at June 30, 2025, were $6.1 million, an increase from $3.3 million at the end of the previous fiscal year [7][9] Capital Structure - The company completed a $6 million registered direct offering in June 2025, with potential additional proceeds of $9.8 million upon full warrant exercise [3][6] - Citius Oncology, a subsidiary, raised $9 million in gross proceeds from a public offering in July 2025 [1][3] Product Pipeline - Citius Pharma's late-stage pipeline includes LYMPHIR™, Mino-Lok®, and CITI-002 (Halo-Lido), with ongoing engagement with the FDA for next steps on these programs [6][3]

Core Viewpoint - Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million, with potential additional proceeds of up to $9.8 million from short-term warrants [1][3]. Group 1: Offering Details - The offering consisted of 4,920,000 shares of common stock priced at $1.22 per share, along with short-term warrants to purchase an additional 9,840,000 shares [1][3]. - The short-term warrants have an exercise price of $1.00 per share, are immediately exercisable, and will expire 24 months from the initial exercise date [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support the commercial launch of LYMPHIR™, including milestone and regulatory payments, as well as general corporate purposes [3]. Group 3: Company Background - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA for treating cutaneous T-cell lymphoma [6]. - The company also has a late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [6].

Core Viewpoint - Citius Pharmaceuticals Inc. has announced a definitive agreement to purchase 1,739,131 shares of its common stock at a price of $1.15 per share, with expected gross proceeds of approximately $2 million to support the commercial launch of LYMPHIR™ and general corporate purposes [1][2]. Group 1 - The offering is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. - The closing of the offering is anticipated to occur on or about April 2, 2025, pending customary closing conditions [1]. - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on March 1, 2024 [3]. Group 2 - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA in August 2024 for treating cutaneous T-cell lymphoma [5]. - The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, with both products having completed pivotal trials in 2023 [5]. - Citius Pharma owns 92% of Citius Oncology, Inc., indicating a strong position in the oncology sector [5].